| Previous Close | 6.86 |
| Open | 6.96 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 1000 |
| Day's Range | 6.62 - 7.01 |
| 52 Week Range | 4.82 - 14.94 |
| Volume | 719,509 |
| Avg. Volume | 1,312,300 |
| Market Cap | 452.869M |
| Beta (3Y Monthly) | 2.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced FDA clearance of the company’s Investigational New Drug Application (IND) for seladelpar to treat primary sclerosing cholangitis (PSC). The company intends to initiate a Phase 2 study to evaluate the safety, tolerability, and efficacy of seladelpar in patients with PSC in the third quarter. PSC is a rare, chronic cholestatic liver disease that is characterized by diffuse inflammation and fibrosis of the bile ducts.
CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that Sujal Shah, President and Chief Executive Officer, will participate in a fireside chat at Raymond James Life Sciences and MedTech Conference on Wednesday, June 19, 2019 at 8:00 a.m. ET (5:00 a.m. PT) at the Lotte New York Palace in New York City. A live audio webcast of the presentation can be accessed through the Investors section of the CymaBay Therapeutics corporate website at http://ir.cymabay.com/events. Seladelpar is a potent, selective, orally active PPARδ agonist that is in development for the treatment of the liver diseases PBC and NASH.
- Reductions in liver fat were minimal and not significant compared to placebo- Reductions in markers of liver injury were robust and clinically meaningful- Seladelpar.
Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH). A poster presentation titled “Capturing the experience and impact of itch in patients with primary biliary cholangitis (PBC),” highlighted results from a qualitative study designed to understand the experience and impact of itch on PBC patients and to examine the validity of three existing pruritus patient-reported outcome (PRO) measures (Itch Numeric Rating Scale (NRS), 5-D Itch Scale, and the Itch Visual Analogue Scale (VAS)).
NEWARK, Calif., May 08, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary biliary cholangitis (PBC) will be presented in poster sessions at Digestive Disease Week® (DDW) in San Diego, California from May 18 – 21, 2019. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH). The presentations will include new data1 from a qualitative study in collaboration with the PBCers Organization, the Canadian PBC Society, and Evidera highlighting itch (pruritus) as a significant symptom for PBC patients with multiple impacts.
NEWARK, Calif., April 30, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced positive results from its Phase 2 study of seladelpar in a subset of cirrhotic patients with primary biliary cholangitis (PBC). Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH). In an oral presentation titled “Seladelpar for the treatment of primary biliary cholangitis: Experience with 25 cirrhotic patients,” Marilyn J Mayo MD, Associate Professor at the University of Texas, Southwestern Medical Center in Dallas, will be reporting the results of a subset of patients with compensated cirrhosis (Child-Pugh A) from an ongoing Phase 2 study designed to assess the safety and efficacy of seladelpar at a daily dose of 5 mg or 10 mg in PBC patients who had an inadequate response (alkaline phosphatase [AP] ≥ 1.67 x upper limit of normal [ULN]) or an intolerance to ursodiol and a total bilirubin ≤ 2 mg/dL.
CymaBay Therapeutics, Inc. (CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver CongressTM of the European Association for the Study of Liver (EASL) in Vienna, Austria from April 10th – 14th. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH).
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEWARK, Calif., March 12, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative.
CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet need, today announced the closing of its previously announced underwritten public offering of its common stock. CymaBay sold 9,200,000 shares of its common stock in the offering, including 1,200,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $12.50 per share before underwriting discounts and commissions. All of the shares of common stock were offered by CymaBay.
CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions. In addition, CymaBay has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price less underwriting discounts and commissions. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.
CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering.
NEWARK, Calif., Feb. 28, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEWARK, Calif., Feb. 21, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
NEWARK, Calif., Feb. 20, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY), today announced the early completion of enrollment in a Phase 2b dose-ranging, paired liver biopsy study of seladelpar for the treatment of nonalcoholic steatohepatitis (NASH). The company expects to report 12-week topline results on changes in liver fat and key biochemical parameters in the second quarter.
CymaBay Therapeutics, Inc. (CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Seladelpar is an orally administered, potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently being evaluated in a global, Phase 3 registration study, ENHANCE, for patients with PBC.
NEWARK, Calif., Jan. 02, 2019 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEWARK, Calif., Nov. 20, 2018 -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY) presented data from its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). Presentations were delivered during two late-breaking presentations yesterday at The Liver Meeting® 2018 hosted by the American Association for the Study of Liver Diseases, as well as multiple additional clinical and pre-clinical presentations. Seladelpar is an orally administered, potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH).
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Nov. 06, 2018 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused.